Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SRI 31215 TFA 是 matriptase、hepsin、肝细胞生长因子激活剂(HGFA)的三重抑制剂,IC50值分别为 0.69 μM、0.65 μM、0.3 μM。它能够阻断 pro-HGF 的活化,模拟 HAI-1/2 的活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 597 | 现货 | ||
2 mg | ¥ 878 | 现货 | ||
5 mg | ¥ 1,490 | 现货 | ||
10 mg | ¥ 2,320 | 现货 | ||
25 mg | ¥ 3,970 | 现货 | ||
50 mg | ¥ 5,670 | 现货 | ||
100 mg | ¥ 7,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,750 | 现货 |
产品描述 | SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, |
靶点活性 | Hepsin:0.65 μM , HGFA:0.3 μM, Matriptase:0.69 μM |
体外活性 | SRI 31215 inhibits fibroblast-induced MET activation, epithelial-mesenchymal transition and migration of cancer cells.?SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGF-producing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors.?Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. |
细胞实验 | DU145 cells were cultured in 6-well tissue culture plates at a density of 1 103 cells per well.?After colonies formed (6-8 days), cells were serum-starved overnight and were then treated with recombinant HGF (10 ng/ml) or with conditioned media from 18Co fibroblasts in the presence or absence of SRI 31215 (10 μM) or the MET kinase inhibitor JNJ 38877605 (1 μM) for 24 hours.?Cells were washed with PBS and colonies were fixed and stained with 0.5% crystal violet solution in 6% glutaraldehyde. |
别名 | SRI 31215 |
分子量 | 533.6 |
分子式 | C27H34F3N5O3 |
CAS No. | 1832686-44-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (38.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8741 mL | 9.3703 mL | 18.7406 mL | 46.8516 mL |
5 mM | 0.3748 mL | 1.8741 mL | 3.7481 mL | 9.3703 mL | |
10 mM | 0.1874 mL | 0.937 mL | 1.8741 mL | 4.6852 mL | |
20 mM | 0.0937 mL | 0.4685 mL | 0.937 mL | 2.3426 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SRI 31215 TFA 1832686-44-8 Tyrosine Kinase/Adaptors c-Met/HGFR SRI-31215 SRI 31215 inhibit SRI31215 Inhibitor inhibitor